Skip to main content
. Author manuscript; available in PMC: 2013 Apr 28.
Published in final edited form as: Clin Cancer Res. 2011 Oct 28;17(24):7595–7604. doi: 10.1158/1078-0432.CCR-11-1456

Table 1. BRAFV600E and PDGFRA Status of Pediatric MAs.

Thirty patients from St Jude Children Research Hospital and 28 patients from the Institute of Cancer Research were screened for the presence of BRAFV600E and PDGFRA amplifications. Diagnosis, age at diagnosis, and PDGFRA amplification status are also shown.

St Jude's Cohort
(30 patients)		 BRAFV600E Wildtype BRAF All
Diagnosis- AA 0 8 8
Diagnosis-GBM 3 19 22
Median Age at Diagnosis
(months)		 165.2 (128–198) 111 (9–213) 117 (9–213)
PDGFRA Amplification 0 4 4
Institute of Cancer
Research Cohort
(28 patients)		 BRAFV600E Wildtype BRAF All
Diagnosis- AA 0 6 6
Diagnosis-GBM 3 19 22
Median Age at Diagnosis
(months)		 146 (79–240) 137 (5–272) 138 (5–272)
PDGFRA Amplification 0 3 3

AA = Anaplastic Astrocytoma; GBM = Glioblastoma. For individual patient data, refer to supplemental Tables 1 & 2.